ホスホイノシチド3-キナーゼ(PI3K)阻害剤の世界市場2019-2023

◆英語タイトル:Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market 2019-2023
◆商品コード:IRTNTR31677
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年7月20日
◆ページ数:127
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:アジア、ヨーロッパ、北米、その他
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥330,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

Technavio社の本調査レポートでは、ホスホイノシチド3-キナーゼ(PI3K)阻害剤の世界市場について調べ、ホスホイノシチド3-キナーゼ(PI3K)阻害剤の市場状況、市場規模、市場予測、市場環境、顧客状況、市場動向、関連企業情報などをまとめました。また、ホスホイノシチド3-キナーゼ(PI3K)阻害剤の市場規模をセグメンテーション別(用途別(CLL、FL、その他の疾患)、)と地域別(アジア、ヨーロッパ、北米、その他)に分けて算出しました。Technavio社はホスホイノシチド3-キナーゼ(PI3K)阻害剤の世界市場規模が2019-2023期間中に年平均5%成長すると予測しています。
・サマリー
・レポートの範囲
・ホスホイノシチド3-キナーゼ(PI3K)阻害剤の市場状況
・ホスホイノシチド3-キナーゼ(PI3K)阻害剤の市場規模
・ホスホイノシチド3-キナーゼ(PI3K)阻害剤の市場予測
・ホスホイノシチド3-キナーゼ(PI3K)阻害剤の世界環境:ファイブフォース分析
・市場セグメンテーション:用途別(CLL、FL、その他の疾患)
・ホスホイノシチド3-キナーゼ(PI3K)阻害剤の顧客状況
・主要地域別市場規模:アジア、ヨーロッパ、北米、その他
・意思決定フレームワーク
・市場動向・成長要因・課題
・関連企業状況・企業分析
 ...
【レポートの概要】

Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market: About this market

Phosphoinositide 3-kinase (PI3K) inhibitors restricts PI3K enzymes and help in controlling cancer. Technavio’s phosphoinositide 3-kinase inhibitors market analysis considers sales from chronic lymphocytic leukemia (CLL), follicular lymphoma (FL), and other indications. Our analysis also considers the sales of phosphoinositide 3-kinase inhibitors in Asia, Europe, North America, and ROW. In 2018, the CLL segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as high prevalence of CLL and FL and increasing new cases of cancer will play a significant role in the CLL segment to maintain its market position. Also, our global phosphoinositide 3-kinase inhibitors market report also looks at factors such as recent approvals, strategic alliances, and special drug designations. However, low adoption of drugs, clinical trial failures, and stringent regulations may hamper the growth of the phosphoinositide 3-kinase inhibitors industry over the forecast period.

Global Phosphoinositide 3-Kinase (PI3K) inhibitors Market: Overview

Recent approvals

Although many approved therapies are available for various types of blood cancer, the market still witnesses a huge unmet need. Chemotherapies are widely used for the treatment of several types of cancer, including lymphomas. However, chemotherapies have some limitations, which reduces patient adherence toward the treatment. Such factors have fueled exhaustive research on target therapies such as PI3K inhibitors for the treatment of cancer. Several drugs have been approved, such as copanlisib (ALIQOPA) for the treatment of FL, in September 2017. Thus, recent approvals are expected to fuel the PI3K inhibitors market to grow at a CAGR of about 5% during the forecast period.

Reimbursement programs

The cost of PI3K inhibitors is usually high, owing to the complex manufacturing process. This has also had a negative impact on the PI3K inhibitors market for a long time. Therefore, various government bodies have started patient assistance programs to reduce the cost burden on patients and make these treatments available at an affordable price. Thus, the availability of reimbursement programs is expected to fuel the growth of the PI3K inhibitors market size during the forecast period.

For the detailed list of factors that will drive the global phosphoinositide 3-kinase inhibitors market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of few major players, the global phosphoinositide 3-kinase inhibitors market is concentrated. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading phosphoinositide 3-kinase inhibitors manufacturers, that include Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc.

Also, the phosphoinositide 3-kinase inhibitors market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY APPLICATION

Market segmentation by application

Comparison by application

CLL – Market size and forecast 2018-2023

FL – Market size and forecast 2018-2023

Other indications – Market size and forecast 2018-2023

Market opportunity by application

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Expansion of research indications

Reimbursement programs

Growing awareness about cancer

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

Competitive scenario

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Bayer AG

Gilead Sciences Inc.

Novartis AG

TG Therapeutics Inc.

Verastem Inc.

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: Application – Market share 2018-2023 (%)

Exhibit 18: Comparison by application

Exhibit 19: CLL – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: CLL – Year-over-year growth 2019-2023 (%)

Exhibit 21: FL – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: FL – Year-over-year growth 2019-2023 (%)

Exhibit 23: Other indications – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: New cases of cancer in US 2015

Exhibit 25: Other indications – Year-over-year growth 2019-2023 (%)

Exhibit 26: Market opportunity by application

Exhibit 27: Customer landscape

Exhibit 28: Market share by geography 2018-2023 (%)

Exhibit 29: Geographic comparison

Exhibit 30: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Proportion of geriatric population in Asia 2007 and 2017

Exhibit 38: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in Asia

Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 42: Top 3 countries in ROW

Exhibit 43: Key leading countries

Exhibit 44: Market opportunity

Exhibit 45: Drug designations

Exhibit 46: Impact of drivers and challenges

Exhibit 47: Approved drugs with respect to their cancer indications

Exhibit 48: Vendor landscape

Exhibit 49: Landscape disruption

Exhibit 50: Vendors covered

Exhibit 51: Vendor classification

Exhibit 52: Market positioning of vendors

Exhibit 53: Bayer AG – Vendor overview

Exhibit 54: Bayer AG – Product segments

Exhibit 55: Bayer AG – Organizational developments

Exhibit 56: Bayer AG – Geographic focus

Exhibit 57: Bayer AG – Segment focus

Exhibit 58: Bayer AG – Key offerings

Exhibit 59: Bayer AG – Key customers

Exhibit 60: Gilead Sciences Inc. – Vendor overview

Exhibit 61: Gilead Sciences Inc. – Business segments

Exhibit 62: Gilead Sciences Inc. – Organizational developments

Exhibit 63: Gilead Sciences Inc. – Geographic focus

Exhibit 64: Gilead Sciences Inc. – Key offerings

Exhibit 65: Gilead Sciences Inc. – Key customers

Exhibit 66: Novartis AG – Vendor overview

Exhibit 67: Novartis AG – Business segments

Exhibit 68: Novartis AG – Organizational developments

Exhibit 69: Novartis AG – Geographic focus

Exhibit 70: Novartis AG – Segment focus

Exhibit 71: Novartis AG – Key offerings

Exhibit 72: Novartis AG – Key customers

Exhibit 73: TG Therapeutics Inc. – Vendor overview

Exhibit 74: TG Therapeutics Inc. – Business segments

Exhibit 75: TG Therapeutics Inc. – Organizational developments

Exhibit 76: TG Therapeutics Inc. – Key offerings

Exhibit 77: TG Therapeutics Inc. – Key customers

Exhibit 78: Verastem Inc. – Vendor overview

Exhibit 79: Verastem Inc. – Business segments

Exhibit 80: Verastem Inc. – Organizational developments

Exhibit 81: Verastem Inc. – Key offerings

Exhibit 82: Verastem Inc. – Key customers

Exhibit 83: Validation techniques employed for market sizing

Exhibit 84: Definition of market positioning of vendors



【掲載企業】

Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc.

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[ホスホイノシチド3-キナーゼ(PI3K)阻害剤の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆